^
Association details:
| Biomarker: | CAD-ALK fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Excerpt:
…treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumour response.
DOI:
10.1038/bjc.2015.401
